Abstract: A tachykinin receptor antagonist, in particular a neurokinin-1 receptor antagonist, is useful for the treatment or prevention of hot flashes associated with hormonal variation in a patient.

Abstract: The present invention relates to a method for treating or preventing an inflammatory disease or condition in a patient in need thereof comprising concomitantly administering to said patient a PPAR&agr; agonist and a glucocorticoid in amounts that are effective to treat or prevent the inflammatory disease or condition. Pharmaceutical compositions for treating or preventing an inflammatory disease or condition are also encompassed.

Abstract: The present invention relates to a method for treating or preventing cachexia in a patient in need thereof comprising administering to said patient a PPAR&agr; agonist in an amount that is effective to treat or prevent cachexia. Combination therapies and pharmaceutical compositions for treating or preventing cachexia are also encompassed.

Abstract: The invention encompasses a method for treating or preventing an inflammatory disease or condition in a mammalian patient in need of such treatment or prevention comprising administering to said patient a compound that is capable of simultaneously binding PPAR&agr; and PPAR&ggr; or concomitantly administering a compound that selectively binds PPAR&agr; with a compound that selectively binds PPAR&ggr; in an amount that is effective to treat or prevent the inflammatory disease or condition.

Abstract: The invention encompasses a method for preventing the rupture of atherosclerotic plaques in a mammalian patient in need of such prevention comprising administering to said patient a compound that is capable of simultaneously binding or binding and activating PPAR&agr; and PPAR&ggr; or concomitantly administering a selective PPAR&agr; agent with a selective PPAR&ggr; agent in an amount that is effective to prevent the rupture of atherosclerotic plaques. The invention also encompasses a method for increasing atherosclerotic plaque stability in a mammalian patient in need thereof comprising administering to said patient a compound that is capable of simultaneously binding or binding and activating PPAR&agr; and PPAR&ggr; or concomitantly administering a selective PPAR&agr; agent with a selective PPAR&ggr; agent in an amount that is effective to increase plaque stability.

Abstract: This invention provides a method for screening and/or determining the efficacy of known or potential reverse cholesterol transport-enhancing compounds in mammals that avoids the need for measuring cellular protein or mRNA levels and instead employs measurements of CD14 levels in blood.

Abstract: This invention provides a drug combination comprised of a thyroid hormone receptor beta agonist with a fibrate in therapeutically effective amounts, which is useful for reducing cholesterol synthesis, lowering plasma cholesterol levels and lowering plasma triglyceride levels.

Abstract: This invention provides a drug combination comprised of a thyroid hormone receptor beta agonist with a fibrate in therapeutically effective amounts, which is useful for reducing cholesterol synthesis, lowering plasma cholesterol levels and lowering plasma triglyceride levels.

Abstract: The present invention concerns a method of treating sepsis comprising administering a therapeutically effective amount of anti-CD14 antibody molecules. A therapeutic composition comprising anti-CD14 antibody molecules in a pharmaceutically acceptable excipient is also contemplated.

Abstract: The present invention concerns a method of treating sepsis comprising administering a therapeutically effective amount of anti-CD14 antibody molecules. A therapeutic composition comprising anti-CD14 antibody molecules in a pharmaceutically acceptable excipient is also contemplated.

Abstract: The present invention concerns a method of treating sepsis comprising administering a therapeutically effective amount of anti-CD14 antibody molecules. A therapeutic composition comprising anti-CD14 antibody molecules in a pharmaceutically acceptable excipient is also contemplated.

Abstract: The present invention concerns a method of treating sepsis comprising administering a therapeutically effective amount of anti-CD14 antibody molecules. A therapeutic composition comprising anti-CDl4 antibody molecules in a pharmaceutically acceptable excipient is also contemplated.

Abstract: The present invention relates to compositions and methods for neutralizing lipopolysaccharide, and treatment of gram-negative sepsis based therein. Accordingly, the invention is directed to a composition of homogeneous particles comprising phospholipids and a lipid exchange protein, such as phospholipid transfer protein or LPS binding protein. The lipid exchange protein is characterized by being capable of facilitating an exchange protein of lipopolysaccharide into the particles. In a specific embodiment, exemplified herein, the lipid particles are high density lipoprotein particles comprising apolipoprotein A-I (apo A-I), a phospholipid, and cholesterol or a lipid bilayer binding derivative thereof. In a specific example, the phospholipid is phosphatidylcholine (PC). In a specific example, the ratio of phosphatidylcholine:cholesterol:apolipoprotein A-I is approximately 80:4:1.

Abstract: The present invention relates to compositions and methods for neutralizing lipopolysaccharide, and treatment of gram-negative sepsis based thereon. Accordingly, the invention is directed to a composition of homogeneous particles comprising phospholipids and a lipid exchange protein, such as phospholipid transfer protein or LPS binding protein. The lipid exchange protein is characterized by being capable of faciliting an exchange of lipopolysaccharide into the particles. In a specific embodiment, exemplified herein, the lipid particles are high density lipoprotein particles comprising apolipoprotein A-I (apo A-I), a phospholipid, and cholesterol or a lipid bilayer binding derivative thereof. In a specific example, the phospholipid is phosphatidylcholine (PC). In a specific example, the ratio of phosphatidylcholine: cholesterol: apolipoprotein A-I is approximately 80:4:1.

Abstract: The invention relates to anti-inflammatory polypeptides comprising soluble CD14 related polypeptides having amino acids at position 7-10 that are different from the native sequence or having amino acids 1-14 deleted.

Abstract: The invention relates to anti-inflammatory peptides that are based on peptide regions 7-10, 11-14, and 57-64 of CD14.

Abstract: The present invention concerns a method of treating CD14-mediated host inflammatory response to LPS often associated with sepsis comprising administering a therapeutically effective amount of anti-CD14 antibody molecules. A therapeutic composition comprising anti-CD14 antibody molecules in a pharmaceutically acceptable excipient is also contemplated.

Abstract: An antibody to septin, in which septin is an opsonin. Septin is isolated from human serum and is present at high levels in normal serum in distinction to the acute phase protein lipoprotein binding protein (LBP). Septin is an opsonin that is capable of binding to lipopolysaccharide to form a complex that is recognized by a receptor on monocytes, macrophage cells and polymorphonuclear cells, and that possesses an apparent molecular weight of about 90 kD as determined by SDS-PAGE analysis. Utilities of the antibody are provided, and testing procedures, materials in kit form, recombinant materials and procedures, and compositions are likewise set forth.

Abstract: The invention is concerned with the discovery, isolation and purification of an agent or factor named herein the CR3 modulator or CMF-1 that is synthesized by polymorphonuclear leukocytes (PMN) in response to agonists which enhance CD18 activity. The CR3 modulator binds to CD18 and activates its adhesion-promoting ability. The CR3 modulator appears to be transiently produced by PMN as an acidic amphiphilic lipid. The CR3 modulator can be assayed by adding dilutions of a CR3 modulator -containing solution to resting PMN and observing the ability of CR3 to mediate binding of erythrocytes coated with C3bi (EC3bi). The isolation of the CR3 modulator, its biological and physical properties and diagnostic and therapeutic uses are described.

Abstract: The influx of leukocytes into the lung and other organs during sepsis or other infectious or non-infectious trauma can be inhibited by the administration of anti-CD18 monoclonal antibodies. Such inhibition results in a prevention and/or diminishment of organ damage in inflammations and especially in endotoxic shock and adult respiratory distress syndrome.